Long-acting injectable contraception with depot medroxyprogesterone acetate

Area of Science:

• Reproductive Health
• Pharmacology
• Contraception

Background:

• Depot medroxyprogesterone acetate (DMPA) is the sole injectable contraceptive approved in the U.S. since 1992.
• Used globally by millions, DMPA has undergone extensive safety reviews, particularly concerning breast cancer risk.

Purpose of the Study:

• To review the efficacy, safety, and side effect profile of DMPA as a contraceptive.
• To assess the long-term health implications of DMPA use.

Main Methods:

• Review of published data on DMPA's contraceptive efficacy and side effects.
• Analysis of studies on DMPA's impact on menstrual patterns, fertility, bone density, and lipid metabolism.

Main Results:

• DMPA demonstrates over 99% contraceptive efficacy, inhibiting ovulation for at least 14 weeks per 150 mg dose.
• Common side effects include irregular bleeding, decreasing over time, with amenorrhea becoming frequent.
• Long-term use is linked to reduced menstrual blood loss, lower risks of PID and endometrial cancer, but may cause reversible bone density reduction and unfavorable lipid changes.

Conclusions:

• DMPA is a highly effective, safe, convenient, and reversible contraceptive for appropriate patients.
• Benefits such as reduced cancer risk and pelvic inflammatory disease incidence are notable.
• Potential risks, including bone density changes and lipid metabolism alterations, require consideration.